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in Zebrafish and Human Cells
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Michael J. Emch,2 Iddo Friedberg,3 William A.C. Gendron,2 Michael A. Barry,2 Karl J. Clark,2 Drena L. Dobbs,1
Maura A. McGrail,1 Stephen C. Ekker,2,* and Jeffrey J. Essner1,*
Abstract
CRISPR and CRISPR-Cas effector proteins enable the targeting of DNA double-strand breaks to defined loci based
on a variable length RNA guide specific to each effector. The guide RNAs are generally similar in size and form,
consisting of a *20 nucleotide sequence complementary to the DNA target and an RNA secondary structure
recognized by the effector. However, the effector proteins vary in protospacer adjacent motif requirements, nu-
clease activities, and DNA binding kinetics. Recently, ErCas12a, a new member of the Cas12a family, was identi-
fied in Eubacterium rectale. Here, we report the first characterization of ErCas12a activity in zebrafish and expand
on previously reported activity in human cells. Using a fluorescent reporter system, we show that CRISPR-
ErCas12a elicits strand annealing mediated DNA repair more efficiently than CRISPR-Cas9. Further, using our pre-
viously reported gene targeting method that utilizes short homology, GeneWeld, we demonstrate the use of
CRISPR-ErCas12a to integrate reporter alleles into the genomes of both zebrafish and human cells. Together,
this work provides methods for deploying an additional CRISPR-Cas system, thus increasing the flexibility re-
searchers have in applying genome engineering technologies.
Introduction
CRISPR systems have been widely adopted in zebrafish re-
search due to their efficacy and ease of reprogramming
DNA binding activity, which is mediated by a single chime-
ric single guide RNA (sgRNA) molecule.1–3 The CRISPR
toolbox continues to expand, with the identification of
systems that display varying protospacer adjacent motif
(PAM) requirements and produce a different double-strand
break (DSB) architecture.4While Cas9 proteins often hydro-
lyze DNA, leaving a blunt-ended cut three base pairs (bp)
upstream from the 5¢ end of the PAM sequence, Cas12a pro-
teins from Acidaminococcus and Lachnospiraceae spp. hy-
drolyze DNA in a staggered fashion, cutting on the 3¢ side of
the PAM and leaving 5¢ single-stranded overhangs of four
nucleotides.5 The architecture of the DSB and end resection
products is a critical determinant of DNA repair pathway ac-
tivation.6 For example, inducing DNA overhangs with stag-
gered CRISPR-Cas9 nickases targeted to opposite strands
can stimulate precision genome engineering using oligonu-
cleotides.7 Thus, there is demand for CRISPR variants that
generate different DSB architectures and elicit more predict-
able repair outcomes for precision genome engineering.
CRISPR-Cas12a activity has been reported in zebrafish
by injection of sgRNA/Cas12a protein ribonucleoprotein
(RNP) complexes.8,9 In these studies, it was shown that
Cas12a-mediated DNA cleavage could be further en-
hanced by a 34C heat-shock treatment or by co-targeting
of nuclease dead Cas9 (dCas9) to the Cas12a target site, in-
dicating that DNA melting is a potential rate limiting step
for Cas12a. Cas12a resulted in increased efficiency of oli-
gonucleotide incorporation compared to Cas9 into geno-
mic cut sites by homology-directed repair, suggesting the
two enzymes may employ distinct mechanisms and re-
sult in different genomic DNA end resection products.8
A CRISPR-Cas12a system was identified in Eubacterium
rectale and found to be ancestrally related to the type V
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class II family of CRISPR proteins, sharing the greatest sim-
ilarity with Cas12a from Acidaminococcus sp. (AsCas12a;
Fig. 1A). E. rectale Cas12a (ErCas12a) is a 1262 amino
acid protein that is reported to recognize a 5¢-YTTN PAM
and uses a 42 or 56 base guide RNA to recognize and cata-
lyze site-specific DNA cleavage.10 However, in this study
we find that ErCas12a elicits robust nuclease activity with
a TTTT PAM suggesting that the PAM requirement may
actually be YTTN. CRISPR-ErCas12a is active in human
cells,10 but its application for gene targeting in vivo and
in vitro has yet to be described.
Microhomology mediated end joining (MMEJ) is a
DNA repair pathway that uses short regions of homology
between resected DNA ends to drive repair, leading to pre-
dictable outcomes after nuclease targeting.11–13 MMEJ-
based gene editing and targeted integration using MMEJ
has been described in zebrafish and mammalian cells, al-
though the length of the homology arms appears to be
more similar to those employed in single-strand annealing
(SSA).14–17 To use MMEJ/SSA for gene targeting, nucle-
ase targeting of a donor plasmid in vivo liberates a donor
cassette, exposing homology arms that are complementary
to the nuclease cut site in the genome, and thereby directs
integration into genomic DNA. A more general term for
the use of this strategy for gene targeting is ‘‘homology-
mediated end joining’’ (HMEJ).18 We recently reported
high-efficiency gene targeting by HMEJ with short homol-
ogy arms called GeneWeld.19 GeneWeld involves the si-
multaneous cleavage of a donor plasmid and a genomic
target with designer nucleases to reveal 24 or 48 bp ho-
mology arms that can be used by the cellular MMEJ or
SSA machinery for homology-directed repair, leading to
donor integration. GeneWeld works with genomic DSB
generated by either transcription activator-like effector nu-
cleases or CRISPR-Cas9, but other nucleases have not yet
been tested.
Here, we report the successful application of ErCas12a
for gene targeting in zebrafish, widely used to model de-
velopment and disease, and in human cells. Consistent
with its similarity to other Cas12a proteins, high ErCas12a
activity requires a 34C heat-shock treatment in zebrafish.
However, injection of mRNA encoding for ErCas12a is
sufficient to induce DSB activity, and pre-crRNA can
serve as an effective RNA guide for ErCas12a, in con-
trast to reports using previously described Cas12a and re-
lated systems.8,20 We developed a universal pre-crRNA
(U-pre-crRNA) for ErCas12a, which can be used in both
zebrafish and human cells for donor DNA cleavage, and
we show that CRISPR-ErCas12a potently induces strand-
annealing mediated repair (SAMR) in a genomic reporter
locus at efficiencies greater than CRISPR-Cas9. Addition-
ally, CRISPR-ErCas12a promotes GeneWeld activity at
rates similar to CRISPR-Cas9. Finally, we apply Gene-
Weld with ErCas12a in human cells and demonstrate
ErCas12a-mediated targeted integration activity at several
human loci, including the safe harbor locus AAVS1.
Methods
Zebrafish husbandry
Zebrafish were maintained in Aquatic Habitats (Pentair)
housing on a 14 h/10 h light/dark cycle. Wild-type WIK
were obtained from the Zebrafish International Resource
Center. All experiments were carried out under approved
protocols from Iowa State University IACUC.
nErCas12an cDNA cloning
gBlocks were ordered from IDT, with zebrafish codon opti-
mized ErCas12A cDNA sequences based on Inscripta pub-
lic disclosure and the addition of dual NLS sequences at the
5¢ and 3¢ end of the cDNA (Supplementary Table S1). Three
gBlock dsDNA templates were amplified with KOD Hot-
Start DNA polymerase (EMD Millipore) using primers
ErCas12af1/ErCas12aAr1, ErCas12af2/ErCas12ar2, and
ErCas12af3/ErCas12ar3 cut with respective restriction en-
zymes, and four-part restriction cloning into NcoI/SacII
cut pT3TS vector backbone was performed (Plasmid
#46757; Addgene). Sequence of ERCAS12A using primer
walking and a full annotation was confirmed.
Injection protocol
Linear, purified pT3TS-nCas9n or pT3TS-nErCas12an was
used as template for in vitro transcription of capped, poly-
adenylated mRNA with the Ambion T3TS mMessage
mMachineKit.mRNAwaspurifiedusing theQiagenmiRN-
easy Kit. The Cas9 universal sgRNAs were generated
FIG. 1. Characterization and activity of CRISPR-ErCas12a in zebrafish. (A) Phylogenetic relationship between
known CRISPR associated proteins and ErCas12a. Evaluation of branching was ensured by bootstrap statistical
analysis (1,000 replications). (B) Workflow showing dual NLS ErCas12a mRNA and pre-crRNA injection into single-
cell animals. Animals are heat shocked for 4 h and then allowed to develop normally until DNA is isolated and
analyzed. (C) Schematic and sequences of pre-crRNA used to target noto. (D) Schematic and sequences of pre-
crRNA used to target cx43.4. (E) Results displaying the wild-type and top five mutated alleles after AmpliconEZ
analysis of two noto pre-crRNAs and one cx43.4 pre-crRNA.
‰
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using cloning free sgRNA synthesis and purified using
the Qiagen miRNeasy Kit. All ErCas12a pre-crRNA and
crRNA was ordered as custom RNA oligos from Syn-
thego, with sequences described in the Supplementary
Tables. In all experiments, 2 nL of 75pg/pl of ErCas12a
and Cas9 were injected. Unless otherwise noted, 2 nL of
12.5 pg/pl pre-crRNA and/or U-pre-crRNA were injected.
Heat shock protocol
Immediately after injection, embryos were placed in a
34C incubator for 4 h. At 4 h, embryos were sorted for
fertilization, and fertilized embryos were moved to a
28C incubator as normal.
DNA isolation and PCR genotyping
Genomic DNA for PCRwas extracted by digestion of single
embryos in 50mM NaOH at 95C for 30min and neutral-
ized by addition of 1/10th volume 1M Tris-HCl, pH 8.0.
GoTaq Green was used as the DNA polymerase master
mix with the primers listed in Supplementary Table S2.
AmpliconEZ from GeneWiz was used for NGS sequencing
(see below) using primers ErCas12anoto1fEZ and ErCas12-
anoto1rEZ for noto target 1, ErCas12anoto3fEZ and ErCas-
12anoto3rEZ for noto target 3, and cxm7gRNA2fEZ,
cxm7gRNA2rEZ for cx43.4 listed in Supplementary
Table S2. GFP+ embryo 5¢ junction fragments for noto
target 1 and target 3 were PCR-amplified with primer
notojxnf and gfp5¢r listed in Supplementary Table S2.
GFP+ embryo 3¢ junction fragments for noto target 3
were PCR-amplified with primer GFP3¢F and notojxnr
listed in Supplementary Table S2. All junction fragment
products were cloned into pCR4-TOPO vector and se-
quenced (Invitrogen).
Donor vector preparation
Donor vectors were prepared and purified, as described
previously.19 Homology arms are built as follows. One
arm begins 13 bp 3¢ of the PAM, while the other arm be-
gins immediately outside of the 3¢ end of the crRNA tar-
get site. See Figures 3 and 4 for homology arm design,
and Supplementary Table S3 for GeneWeld homology
arm oligos used for Golden Gate cloning. Gene targeting
oligos and donor vector sequences are listed in Supple-
mentary Tables S2 and S3.
Generating noto:RFP-DR48
Zebrafish RFP assay generation, injection, and line
isolation. pPRISM-V3 was PCR amplified with v3f
and v3r to remove the ocean-POUT terminator and add
SgrAI and SpeI cloning sites (Supplementary Table S2).
Bactin 3¢UTRwas PCR amplified using KOD polymerase
with primers bactinf and bactinr to add SgrAI and SpeI en-
zyme sites for sticky end cloning. pPRISM-V3 (pout neg-
ative) amplicon and bactin 3¢ UTR were cut with SgrAI
and SpeI. After ligation with Fisher Optizyme T4 Ligase
and sequence verification to create pPRISM-V3-bactin,
pPRISM-V3-bactin-SSA-DR48 was created by simulta-
neously adding the NBM and creating a direct repeat
with phosphorylated primers DRf and DRr using pPRISM-
V3-bactin with KOD polymerase followed by Fisher Opti-
zyme T4 Ligation and sequence verification. To target
these constructs to noto, homology domains up- and down-
stream of a genomic CRISPR-Cas9 target site were cho-
sen, as described in Wierson et al.19 Oligos flhv35aflh,
flhv35bflh, flhv33aflh, and flhv33bflh, containing the
gene targeting information, were added to pPRISM-V3-
bactin RFP-DR48 using Golden Gate cloning, as described
in Wierson et al.19 The RFP cassette was liberated from
the donor using the same noto sgRNA used to cut the ge-
nome. Gamma-crystalin:eGFP+ embryos were sorted and
raised to adulthood, outcrossed to generate the F1 genera-
tion, and outcrossed again to generate lines of F2s.
Southern blot analysis
Genomic Southern blot and copy number analysis was
conducted, as previously described.21 PCR primers used
for genomic- and donor-specific probes are listed in Sup-
plementary Table S2.
Cell culture
HEK293T cells were obtained from ATCC (CRL-3216).
Cells were maintained in Dulbecco’s modified Eagle’s
medium (Gibco #11995-040) supplemented with 10%
fetal bovine serum (Gibco #26140079) and 1% penicillin/
streptomycin (Gibco #15140-122). Media was changed
every 2–3 days and re-plated at a final dilution of 1:10
maintained at about 750,000 cells/mL.
DNA isolation and sequence analysis
DNA from whole-cell populations was purified using the
Qiagen DNeasy Blood & Tissue Kit (Qiagen 69504).
PCR amplification was performed with MyTaq DNA Pol-
ymerase (Bioline BIO-21108) and purified with the Qia-
gen QIAquick PCR Purification Kit (Qiagen 28104).
Samples used for ICE analysis were submitted to Gene-
Wiz Sanger Sequencing service.
Cloning in vitro ErCas12a construct targeting AAVS1
(pErCas12aErCas12a-AAVS1)
Due to redundant restriction sites in the guide scaffold and
ErCas12a protein, the pX601-AAV-CMV::NLS-SaCas9-
NLS-3xHA-bGHpA;U6::BsaI-sgRNA plasmid (Addgene
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#61591) was digested with BsaI and NotI first to insert the
ErCas12a secondary structure and sgRNA targeting
AAVS1 with ErCas12a sgRNAAAVS1 top and ErCas12a
sgRNA AAVS1 bottom (termed AAV: ErCas12a AAVS1
sgRNA; Table 3). Following this, ErCas12a as well as the
Xenopus globin 5¢ UTR and both N and C termini SV40
NLS signals were amplified from ‘‘T3TS nErCas12an’’
using PCR primers ErCas12a AgeI forward and ErCas12a
BamHI reverse (Supplementary Table S1). The resulting
3.9 kbp PCR fragment was cloned into an Agilent pSC
Strataclone PCR cloning vector (termed ErCas12a Strata-
clone) to amplify the fragment with the desired restriction
sites. ErCas12a Strataclone was digested with AgeI and
BamHI to isolate ErCas12a with ends compatible with the
AAV:ErCas12a AAVS1 sgRNA construct. The px601 plas-
mid was likewise digested with AgeI and BamHI to
remove SaCas9 and replace it with ErCas12a. Plasmids
were screened for insertion of both ErCas12a as well as
the AAVS1 targeting sgRNA (pErCas12a-AAVS1) and
amplified with the Qiagen Endotoxin Free Maxiprep
Kit (Qiagen 12362).
pErCas12a-AAVS1-U
pErCas12a-AAVS1-U was generated by inserting
ErCas12a pre-U-crRNA into AAV 601 by digesting
AAV601 with BsaI+ NotI and inserting annealed oli-
gos ErCas12a UgRNA + Scaffold Top and ErCas12a
UgRNA + Scaffold Bottom. The U6 promoter, the cr-
RNA scaffold, and the U-pre-crRNA were PCR amplified
from AAV 601 using ErCas12a U6 + ugRNA Primer
PfoI Fw and ErCas12a U6 + ugRNA Primer PfoI Rev.
This PCR amplicon as well as pErCas12a-AAVS1 were
digested with PfoI and ligated with T4 DNA ligase to gen-
erate pErCas12a-AAVS1-pre-crRNA1-U-pre-crRNA.
Generating knock-in cassette for AAVS1
The 24 and 48 bp homology arm CMV/GFP/Zeocin resis-
tance knock-in cassettes were generated by designing
PCR primers complementary to the psiRNA-SV40
Early PolyA GFPzeo plasmid (Invivogen) flanked by
the 48 bp of homology and the UgRNA sequence sepa-
rated by a 3 bp spacer. The left 48HA forward primer
AAVSI T1 L48HA and the right 48HA reverse primer
AAVS1 T1 R48HA22 were used to amplify the CMV/
GFP/Zeocin resistance cassette containing the homology
arms and the UgRNA target sequence (Supplementary
Tables S2 and S3). This 2.6 kbp PCR fragment was sub-
sequently cloned into a Strataclone PCR cloning vector
and screened for the insert. Sequence confirmed knock-
in constructs were amplified with the Qiagen Maxiprep
Kit and termed ‘‘pGFP::Zeo-48.’’
Generating ErCas12a EZ clone
nErCas12an was PCR amplified from pT3TSnErCas12an
with Platinum Taq DNA Polymerase HiFi (Thermo
Fisher Scientific #11304011) with ErCas12a AgeI Fw
and ErCas12a BamHI Rev and PCR cloned into the Agi-
lent Strataclone vector (Agilent #240205) to generate
ErCas12a Strataclone. ErCas12a Strataclone was sub-
jected to site-directed mutagenesis with ErCas12a SDM
remove BsaI Top and ErCas12a SDM remove BsaI bot-
tom with the Q5 SDM kit (New England Biolabs
#E0554S) to generate ErCas12a Strataclone no BsaI.
The nErCas12an fragment lacking the BsaI site was re-
moved from the ErCas12a Strataclone no BsaI backbone
by digesting with AgeI and BamHI. Likewise, the
pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;
U6::BsaI-sgRNA plasmid (Addgene #61591) was digested
with AgeI and BamHI and had nErCas12an inserted
into it to generate p601nErCas12an no BsaI. The cr-
RNA scaffold was inserted into the p601nErCas12an
no BsaI by digesting with BsaI and NotI and inserted
the annealed oligos ErCas12a EZ clone scaffold top
and ErCas12a EZ clone scaffold bottom to generate
ErCas12a EZ Clone.
Cloning in vitro ErCas12a construct targeting CCR5
and TRAC
Cr-RNA oligos corresponding to the genomic target site
(e.g., CCR5 sgRNA 1 Top + CCR5 sgRNA 1 Bottom)
were annealed in a thermocycler according to the
Zhang lab protocol. Briefly, oligos were annealed by in-
cubating at 37C for 30min followed by 95C for 5min
and then ramped down to 25C at 5C/min. The annealed
oligo duplex was cloned into ErCas12a EZ clone
Digested with BsaI and ligated by T4 DNA ligase.
pMiniCAAGs:RFP-DR48 RFP assay generation,
transfection, and analysis
pPRISM-V3-bactin SSA-DR48 was PCR amplified with
Platinum Taq DNA polymerase HiFi (Thermo Fisher Sci-
entific #11304011) with Broken RFP Transfer to Tol2
XhoI Fw and Broken RFP Transfer to Tol2 BglII Rev to
add XhoI and BglII restriction sites to the RFP cassette.
pkTol2C-EGFP as well as the RFP amplicon were
digested with XhoI and BglII to create compatible cohe-
sive ends and ligated with T4 DNA ligase to generate
pkTol2CBrokenRFP. In order to the construct to express
episomally in cell culture systems, a Kozak sequence
was added by digesting pkTol2CBrokenRFP with EcoRI
and XhoI and restriction cloning the annealed oligos
Kozak Seq Top and Kozak Seq Bottom to generate
pMiniCAAGs:RFP-DR48.
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ErCas12a constructs targeting the UgRNA were gener-
ated by digesting ErCas12a EZ clone with BsaI and cloning
in the annealed oligos ErCas12a UgRNA BsaI Top and
ErCas12a UgRNA BsaI bottom to generate pErCas12a-U-
pre-crRNA. Cas9 constructs targeting the UgRNA were
generated by digesting lentiCRISPR v2 (Addgene #52961)
with BsmBI and cloning in the annealed oligos Cas9
UgRNA BsmBI Top and Cas9 UgRNA BsmBI Bottom to
generate pCas9-UgRNA. To control for promoter expres-
sion between ErCas12a and Cas9, the CMV promoter was
added to pCas9-UgRNA by digesting ErCas12a EZ clone
with XbaI and AgeI to remove the CMV promoter and
pCas9-UgRNA with NheI and AgeI to replace the native
EF1 alpha promoter.
HEK 293T cells were transfected with 5 lg
pMiniCAAGs:RFP-DR48 and 5lg of either pErCas12a-
U-pre-crRNA or pCas9-UgRNA with the Etta H1 electro-
porator as described above. Cells were assessed for RFP
expression 48 h later by flow cytometry with 584 nm emis-
sion and 607 nm detection.
Transfection
HEK293T cells used for indel acquisition assays were
transfected with Lipofectamine 3000 (Thermo Fisher Sci-
entific #L3000008) according to manufacturer’s protocol
with 5lg of ErCas12a plasmid targeting each site. Cells
used for targeted integration assays were transfected with
Etta H1 electroporator with the following parameters:
200V, 784ms interval, six pulses, 1,000 ls pulse dura-
tion, at a concentration of 20E6 cells/mL at the volume
of 100lL in Etta EB electroporation buffer. Cells are
recovered post electroporation by incubating at 37C
for 5–10min before being plated on a six-well tissue cul-
ture plate at a density of about 1.5E6 cells/mL.
GeneWiz AmpliconEZ: DNA library preparation
and Illumina sequencing
DNA library preparations, sequencing reactions, and ini-
tial bioinformatics analysis were conducted at GENE-
WIZ, Inc. DNA library preparation, clustering, and
sequencing reagents were used throughout the process
using the NEBNext Ultra DNA Library Prep Kit, follow-
ing the manufacturer’s recommendations (Illumina).
End-repaired adapters were ligated after adenylation of
the 3¢ ends followed by enrichment by limited cycle
PCR. DNA libraries were validated on the Agilent
TapeStation, quantified using the Qubit 2.0 Fluorometer
(Invitrogen), and multiplexed in equal molar mass. The
pooled DNA libraries were loaded on the Illumina instru-
ment according to the manufacturer’s instructions. The
samples were sequenced using a 2 · 250 paired-end
(PE) configuration. Image analysis and base calling
were conducted by the Illumina Control Software on
the Illumina instrument.
Data analysis
The raw Illumina reads were checked for adapters and
quality via FastQC. The raw Illumina sequence reads
were trimmed of their adapters and nucleotides with
poor quality using Trimmomatic v0.36. Paired sequence
reads were then merged to form a single sequence if
the forward and reverse reads were able to overlap. The
merged reads were aligned to the reference sequence,
and variant detection was performed using the GENE-
WIZ proprietary Amplicon-EZ program.
Phylogeny and homology analysis
The amino acid sequence (ErCas12a) was used for ho-
mology search by the Blastp tool against the non-
redundant (nr) database. The homologous sequences
were then retrieved from the NCBI database. Multiple se-
quence alignment was done using the CLUSTAL Omega
webserver. The phylogenetic tree was constructed using
the maximum likelihood method based on JTT matrix-
based model in MEGA v7.0.18.23 Evaluation of branch-
ing was ensured by bootstrap statistical analysis (1,000
replications).
Phylogenetic analysis
The phylogenetic tree relationship of ErCas12a from
E. rectale and other related Cas proteins available in
the NCBI database was constructed using the maximum
likelihood method with MEGA v7. The numbers above
and below the branch points specify the confidence levels
meant for the relationship of the paired sequences as es-
timated by the bootstrap analysis. Branch lengths are
measured as the number of substitutions per site. Cas
protein sequences used for phylogenetic analysis
are CRISPR-associated endonuclease Cas12b from
Alicyclobacillus acidoterrestris, CRISPR-associated
Endonuclease Cas9 from Streptococcus pyogens,
CRISPR-associated Endonuclease Cpf1 from Acidami-
nococcus sp. BV3L6, type V CRISPR-associated pro-
tein Cpf1 from Lachnospiraceae bacterium ND2006,
and type V CRISPR-associated protein Cpf1 from Fran-
cisella tularensis.
Cas variant homology alignments
Multiple sequence alignment of ErCa12a with homolo-
gous Cas proteins such as CRISPR-associated endonucle-
ase Cas12b from A. acidoterrestris, CRISPR-associated
Endonuclease Cas9 from S. pyogens, CRISPR-associated
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Endonuclease Cpf1 from Acidaminococcus sp. BV3L6,
type V CRISPR-associated protein Cpf1 from Lachnospir-
aceae bacterium ND2006, and type V CRISPR-associated
protein Cpf1 from F. tularensis. Six representative se-
quences were used for alignments with Clustal Omega
webserver.
Determining nuclease genome coverage
Sites were discovered using the fuzznuc nucleotide pat-
tern sequence analyzer from EMBOSS v6.5.7.24 Human
sites were determined from whole-genome assembly
GRch38 downloaded from Ensembl release 97 (ftp://
ftp.ensembl.org/pub/release-97/fasta/homo_sapiens/dna/
Homo_sapiens.GRCh38.dna.primary_assembly.fa.gz).
Zebrafish sites were determined from whole-genome
assembly GRCz11 downloaded from Ensembl release 97
(ftp://ftp.ensembl.org/pub/release-97/fasta/danio_rerio/dna/
Danio_rerio.GRCz11.dna.primary_assembly.fa.gz). Match-
ing hits were tabulated using egrep for each pattern set.
Results
ErCas12a induces indels in zebrafish embryos
We used informatic analyses to categorize a new potential
gene editor (GenBank Accession no. MH347339.1) that
aligns as a novel Cas12a protein: ErCas12a (Fig. 1A
and Supplementary Fig. S1). To determine the utility of
ErCas12a targeting in the human and zebrafish genomes,
we enumerated the amount of ErCas12a’s YTTN PAM
sites compared to Cas9’s NGG PAM sites. We found that
across the zebrafish genome, ErCas12a has 168,074,842 po-
tential YTTN PAM targets, and Cas9 has 95,376,529 NGG
PAMs. In humans, ErCas12a has 345,066,663 YTTN
PAMs as opposed to Cas9’s 304,420,059 NGG PAMs.
This expanded coverage for ErCas12a increases the geno-
mic accessibility in AT-rich genomes, such as zebrafish,
otherwise inaccessible to Cas9.
To assess the activity of ErCas12a, we first synthesized
a codon-optimized version for expression in eukaryotes
and added dual SV40 nuclear localization signals
(NLS) at the N- and C-termini, as dual NLS was shown
to increase efficacy of Cas9 in zebrafish.3 To test
ErCas12a gene-editing activity in vivo, ErCas12a
mRNA was co-injected with a pre-crRNA into single-
cell zebrafish embryos followed immediately by heat
shock at 34C for 4 h (Fig. 1B). Three pre-crRNAs and
one crRNA were designed to target exon 1 of the zebra-
fish noto gene (Fig. 1C). Co-injection of ErCas12a
mRNA with noto-pre-crRNA1 and incubation at 28C
did not result in gene-editing activity, similar to previous
reports using Cas12a (Moreno-Mateos et al.8 and data
not shown). However, injection of ErCas12a mRNA
with noto-pre-crRNA1 or noto-pre-crRNA3 followed
by a 4 h 34C heat shock resulted in phenotypes charac-
teristic of biallelic loss of noto, including loss of the no-
tochord and a shortened tail,25 at efficiencies ranging
from 7% to 61% (Supplementary Fig. S2A). We noted
no difference in nuclease activity between two concentra-
tions of pre-crRNA and chose the lower dose moving for-
ward to decrease the potential for RNA toxicity.
Polymerase chain reaction (PCR) across these individual
target sites and subsequent heteroduplex mobility shift
assays revealed the presence of indels characteristic of re-
pair by non-homologous end joining (NHEJ) activity
(Supplementary Fig. S2B), which we then confirmed
and quantified by next-generation sequencing (NGS), as
described below. noto-pre-crRNA2 and noto-crRNA1
did not elicit a phenotype, and heteroduplex mobility
shift assays across those targets indicate they are inac-
tive sgRNAs (data not shown). Efficiencies of biallelic
noto inactivation at the same target varied considerably
from injection to injection (Supplementary Fig. S2),
consistent with previous reports in human cells and
zebrafish using CRISPR-Cas12a8,20,26,27 To confirm
that our results were not specific to a single locus, we
injected ErCas12a mRNA and pre-crRNA to target
two sites in the cx43.4 gene (Fig. 1D). PCR across
the individual target sites and subsequent restriction
fragment length polymorphism (RFLP) analysis dem-
onstrated that cx43.4-pre-crRNA2 was active (Supple-
mentary Fig. S2D), while cx43.4-pre-crRNA1 was
inactive (data not shown).
To gain a better understanding of the frequency of
ErCas12a insertion/deletion (indel) events, we used Illu-
mina NGS to analyze the efficiencies of mutation at the
active noto and cx43.4 target sites. DNA amplicons
from five noto mutant embryos injected with ErCas12a
mRNA and noto-pre-crRNA1 or noto-pre-crRNA3 and
five cx43.4 pre-crRNA1 injected embryos were selected
randomly for NGS. As expected for biallelic inactivation
at noto, *61% of alleles at noto-pre-crRNA1 showed
indels, characteristic of NHEJ and/or MMEJ after nucle-
ase targeting (Fig. 1E). The more efficient noto-pre-
crRNA3 showed *90% of alleles containing indels
(Fig. 1E). However, in agreement with the RFLP analy-
sis, the majority (*74%) of alleles sequenced at cx43.4
had the wild-type sequence, indicating that not all target-
ing events with ErCas12a are efficient enough to produce
biallelic mutation of the target locus (Fig. 1E). Taken to-
gether, these data indicate CRISPR-ErCas12a introduced
as an RNA system can be active in zebrafish with a 34C
heat shock, and that pre-crRNA can serve as an active
RNA guide for directing ErCas12a activity to genomic
target sites.
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ErCas12a elicits SAMR more efficiently than SpCas9
in a genomic reporter system in zebrafish
We next employed a stably integrated red fluorescent
protein (RFP) reporter system to compare visually the ef-
ficiencies with which CRISPR-Cas9 and CRISPR-
ErCas12a differentially elicit DNA repair using SAMR.
We used GeneWeld to create a transgenic line of zebra-
fish that contained a single copy of an SAMR reporter,
noto:RFP-DR48 (Fig. 2A and Supplementary Fig. S3).
The RFP coding sequence is disrupted by a target cassette
engineered with Cas9 and ErCas12a sites that is flanked
by 48 bp of direct repeat sequence. A DSB and end resec-
tion in the target liberates the 48 nucleotide direct repeats,
which can restore the RFP reading frame after SAMR,
leading to a semi-quantitative read-out of repair efficien-
cies. Injection of single-cell noto:RFP-DR48 trans-
genic embryos with Cas9 mRNA and universal guide
RNA (UgRNA) results in RFP expression in the noto-
chord, indicative of SAMR after CRISPR-Cas9 targeting
(Fig. 2B and Supplementary Table S4).
We then tested whether CRISPR-ErCas12a promotes
SAMR in the noto:RFP-DR48 assay. We designed a U-
pre-crRNA, with no predicted off-target sites in zebrafish
or human cells, to direct ErCas12a activity to noto:RFP-
DR48. Injection of ErCas12a mRNA and U-pre-crRNA
resulted in RFP expression in the notochord (Fig. 2B
and C). Based on the percentage of injected animals
with RFP+ notochords, ErCas12a elicited SAMR at a
higher frequency than SpCas9 (Fig. 2B–D). Injected em-
bryos were highly mosaic and qualitatively sorted into
three classes of notochord RFP expression pattern:
broad, intermediate, and narrow (Fig. 2E–G). While
*70% of ErCas12a-injected animals showed RFP+
cells in the notochord as opposed to *40% in SpCas9-
injected embryos, ErCas12a repair events are equally
mosaic (Figure 2B–D). These results indicate that
noto:RFP-DR48 is a viable assay for screening the pro-
pensity of designer nucleases to elicit SAMR and that
in this context ErCas12a preferentially activates SAMR
at rates higher than Cas9.
Using ErCas12a for precise integrations in zebrafish
We leveraged the activity of the U-pre-crRNA to deter-
mine whether CRISPR-ErCas12a can catalyze targeted
integration of fluorescent reporters using GeneWeld.19
First, we injected nErCas12an, noto-pre-crRNA1, U-pre-
crRNA, and a green fluorescent protein (GFP) reporter
plasmid programmed with the U-pre-crRNA target site
and 24 bp of homology 5¢ to the noto-crRNA1 genomic
site to promote gene targeting at noto (Supplementary
Fig. S4A and Supplementary Table S5). Fluorescent pos-
itive notochord cells were observed at the 18-somite
stage, indicating in-frame integration of the GFP cas-
sette at noto (Supplementary Fig. S4B and B¢). On
average, 24% of embryos injected display targeted
noto integrations (Supplementary Fig. S4C). However,
notochords were highlymosaic, indicating a low efficiency
of somatic integration activity in tissue types that form the
notochord (Supplementary Fig. S4B and B¢). GFP was
often observed outside of the notochord yet in the meso-
derm, as expected with biallelic disruption of noto and
transfating of notochord cells.21 Junction fragment PCR
was conducted on GFP+ embryos to confirm that integra-
tion was directed by the programmed homology. The
expected PCR band was recovered in GFP+ embryos,
while no PCR band was detected in the control experiment
performed without the genomic pre-crRNA (Supplemen-
tary Fig. S4D and E). DNA sequencing confirmed precise
junctions at the 5¢ end of the integration (Supplementary
Fig. S4F).
We next designed a GeneWeld donor with both 5¢ and
3¢ homology domains flanking the GFP cassette to pro-
mote precise repair at both sides of the integration site
(Fig. 3A).19 Targeting noto using pre-crRNA3 with Gen-
eWeld resulted in an average of 31% of embryos with
GFP+ notochords (Fig. 3B, B¢, and C and Supplementary
Table S5). Most notochords were highly mosaic and dis-
played GFP expression indicative of lost cell fate, as in
noto target 1 targeting (Supplementary Fig. S4B), al-
though some events were recovered in which >90% of
the notochord expressed GFP (Fig. 3B). Predicted 5¢
FIG. 2. Using noto:RFP-DR48 to assay the propensity of ErCas12a and SpCas9 to elicit strand annealing in
zebrafish. (A) Schematic of noto:RFP-DR48 showing the location of the 48 bp direct repeats flanking both the
SpCas9 and ErCas12a universal RNA cursor sites (underline) and protospacer adjacent motif (PAM) sites (red text).
(B) Data plot showing the ratio of injected animals displaying red fluorescent protein (RFP) in the notochord out
of the total carrying the transgene. Data plot represents the mean – SD. p-Values calculated with one-tailed
Student’s t-test. (C) Qualitatively scored ratios of notochord converted to RFP+ after SpCas9 induced strand-
annealing mediated repair (SAMR). (D) Qualitatively scored ratios of notochord converted to RFP+ after ErCas12a
induced SAMR. (E–G and E’-G’) Representative embryos for broad, intermediate, and narrow conversion of RFP in
the notochord.
‰
424 WIERSON ET AL.
425
FIG. 3. Targeting noto with GeneWeld. (A) Schematic of noto showing designed homology for precise integration
using ErCas12a and the U-pre-crRNA. Green is designed 5¢ homology. Blue is designed 3¢ homology. The PAM for
ErCas12a targeting in the genome and donor is underlined. (B and B¢) Confocal Z-stack image showing broad
green fluorescent protein (GFP) expression in the embryo. Scale bar is 100 lm. (C) Data plot showing the ratio of
embryos with GFP expression in the notochord out of total injected embryos. Data plot represents the mean – SD.
(D) Gel showing 5¢ junction fragment expected after precise integration using GeneWeld. (E) Gel showing 3¢
junction fragment expected after precise integration using GeneWeld. (F) DNA sequencing of lane 5 in (D) and (E)
showing a precise integration using the programmed homology.
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and 3¢ junction fragments were recovered by PCR in
GFP+ embryos (Fig. 3D and E), and junction fragment
sequencing from a single embryo demonstrated precise
integration at both ends of the cassette (Fig. 3F). These
data indicate that ErCas12a can be an effective nuclease
for catalyzing integration in zebrafish using GeneWeld.
However, we note both qualitative as well as quantitative
differences. For example, the requirement for the heat-
shock step imposes a potential delay on ErCas12a activ-
ity compared to SpCas9, and this kinetic difference can
explain the higher mosaicism for Ercas12a compared to
SpCas9 in this integration method.
ErCas12a induces DSB in human cells
We developed an all-in-one vector for expression of the
dual nuclear localization signal ErCas12a and a pre-
crRNA in vitro (Fig. 4A). We targeted two therapeuti-
cally relevant safe harbor loci: AAVS1 and CCR528
(Fig. 4B and D). We additionally targeted the TRAC
locus due to its reported significance in generating chime-
ric antigen receptor T cells (Fig. 4E).29 In vitro cleavage
activity of ErCas12a with our expression system was
assessed using a T7 endonuclease (T7EI) assay to deter-
mine whether a DSB and subsequent indels were induced
at the AAVS1 locus after transfection into HEK293T
cells. The expected banding pattern was apparent in
DNA amplified from pErCas12a-AAVS1-pre-crRNA1
transfected cells but not control cell DNA, indicating
that ErCas12a was active at the AAVS1 target site
(Fig. 4C). No indel activity was detected at the AAVS1
pre-crRNA2 site by T7E1 assay (data not shown).
These data suggest that the all-in-one expression system
is functional in vitro.
To gain a quantitative understanding of the cleavage
activity of ErCas12a at the AAVS1, CCR5, and TRAC tar-
get sites, PCR amplicons were submitted for Sanger se-
quencing and analyzed using ICE software, which
infers CRISPR activity from sequencing trace reads.30
ICE analysis showed targeting AAVS1 with ErCas12a,
and pre-crRNA1 created indels in 58% of sequenced
amplicons (Fig. 4F and Supplementary Table S6). Tar-
geting CCR5 with ErCas12a at four sites resulted in a
range of mutagenesis efficiency from 20% to 60%
(Fig. 4F and Supplementary Table S6). Similarly, we
tested four pre-crRNAs targeting TRAC and found the
most efficient resulted in 60% of sequenced amplicons
contained indels (Fig. 4F and Supplementary Table S6).
Because ICE is based on Sanger sequencing data,
which considers fewer reads than NGS, it is likely to un-
derestimate the true percentage of indels. We therefore
measured indel activity at the AAVS1-pre-crRNA1 target
site using Illumina sequencing, which showed that
*74% of recovered alleles were edited (Fig. 4G).
Taken together, these data demonstrate that ErCas12a is
active in human cells at clinically relevant genomic loci.
ErCas12a elicits SAMR more efficiently than SpCas9
in an episomal reporter system in human cells
As ErCas12a was shown to induce SAMR in a stable
transgenic in zebrafish at least as efficiently as Cas9,
we next tested whether the same was also true in
human cells with an episomal analog of the zebrafish ex-
periment. Episomal reporters have been used routinely in
cell culture systems to assay DNA repair pathways and
identify the proteins involved.31–34 We modified the
noto:RFP-DR48 cassette for use as a reporter in mam-
malian cell culture, creating pMiniCAAGs:RFP-DR48
(Fig. 5A). As observed in zebrafish, transfection of
pMiniCAAGs:RFP-DR48 with a nuclease and requisite
sgRNA into human cells is expected to promote a DSB
at the nuclease target site, resulting in a fluorescent readout
of nuclease activity if SAMR is used to repair the DSB.
Transfection of HEK293T cells with pMiniCAAGs:
RFP-DR48 and pErCas12a-U-pre-crRNA or pCas9-
UgRNA resulted in RFP+ cells, demonstrating efficient
SAMR with both ErCas12a and Cas9 nucleases (Fig. 5A).
Quantification of RFP+ cells by flow cytometry indicated
SAMR induction was significantly greater ( p< 0.0044)
with ErCas12a compared to SpCas9 (Fig. 5B and Supple-
mentary Fig. S5). Together, these results show ErCas12a
nuclease has similar cleavage activity in human cells and
zebrafish, and is more efficient than Cas9 in mediating
SAMR in vivo and in vitro.
ErCas12a promotes precise integration
in human cells
Because of AAVS1’s utility in therapeutic expression of
transgenes, we next wanted to determine whether
ErCas12a could mediate precise transgene insertion at
the pre-crRNA1 site in AAVS1.35–37 To test this, we
used the GeneWeld strategy to mediate integration of a
pCMV:GFP::Zeo reporter containing 48 bp 5¢ and 3¢
arms homologous to the AAVS1 pre-crRNA1 site
(Fig. 6A and B). HEK293T cells were transfected with
the pCMV:GFP:Zeo donor plasmid and the all-in-one
pErCas12a-AAVS1-U plasmid that expresses ErCas12a,
AAVS1 pre-crRNA1, and U-pre-crRNA (pErCas12a-
AAVS1-U). Transfections were also done with the
pCMV:GFP:Zeo-48 donor plasmid and pErCas12a-
AAVS1 pre-crRNA1 without the U-pre-crRNA, or
pCMV:GFP:Zeo-48 donor plasmid alone. GFP+ cells
were isolated by fluorescence-activated cell sorting
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(FACS) 1 day post electroporation to control for plasmid
delivery, and then screened for stable integration by flow
cytometry 2 weeks post transfection to measure dropout
of GFP+ cells (Fig. 6C and Supplementary Fig. S6).
The data revealed a significant 2.5-fold increase
( p < 0.0003) in the number of cells that remained GFP+
when transfected with the donor molecule, ErCas12a
and the pre-crRNA, compared to the donor alone control
(Fig. 6D and Supplementary Fig. S6B–C†). GFP+ cell
populations were screened for targeted integration at
the AAVS1 pre-crRNA1 site by junction fragment PCR
and sequencing. The 5¢ junction analysis showed precise
repair at the integration site in the cell population trans-
fected with pErCas12a-AAVS1-U and the donor
(Fig. 6E and F) but was absent in the donor alone popu-
lation. These data suggest ErCas12a is a tractable
FIG. 4. ErCas12a activity in human HEK293T cells. (A) Schematic showing the workflow for ErCas12a and pre-
crRNA expression in human cells from a cis expression plasmid. After transfection, cells are recovered and then
analyzed. (B) Schematic of two pre-crRNAs designed to target AAVS1. (C) T7E1 assay showing AAVS1-pre-crRNA1 is
active. Arrowheads are cleaved bands, indicating nuclease activity. (D) Schematic of four pre-crRNAs designed to
target CCR5. (E) Schematic of four pre-crRNAs designed to target TRAC. (F) Graph showing percentage of indels
after using pre-crRNAs to target AAVS1, CCR5, and TRAC in HEK293T cells as determined by ICE analysis. Data plot
represents the mean – SD. (G) Results displaying the wild-type and top five mutated alleles after AmpliconEZ
analysis of AAVS1 targeted DNA.
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nuclease for GeneWeld-mediated precision integration at
the AAVS1 safe harbor locus in human cells.
Discussion
In this report, we establish that CRISPR-ErCas12a is an
active nuclease in zebrafish and explore its use in
human cells, demonstrating its ability to serve as an
efficient alternative to CRISPR-Cas9 for generating
HMEJ-mediated gene targeting events in vitro and
in vivo. Targeting in zebrafish embryos, we created
frame shift indel alleles in the noto and cx43.4 at up to
*90% and *24%, respectively. ErCas12a activity is
temperature-dependent in zebrafish and requires a 34C
heat shock for activity. In a genomic reporter assay,
ErCas12a elicits SAMR in a reporter assay at levels nearly
twofold greater than Cas9 in both zebrafish and human
cells. ErCas12a is also a viable nuclease for mediating
gene targeting using the GeneWeld strategy in zebrafish
and human cells. We detected robust DSB induction at
three therapeutically relevant human loci and demon-
strated that ErCas12a is effective for directing GeneWeld
integrations at the AAVS1 locus in human cells. These re-
sults suggest that ErCas12a could be employed as a tracta-
ble nuclease for gene editing across multiple species for
both basic research and clinical applications.
In prior reports of CRISPR-Cas12a activity in zebra-
fish, appreciable nuclease activity with a sgRNA was
only observed after RNP delivery and heat shock.8,20
While still requiring a heat shock but in contrast to pre-
viously described Cas12a systems, ErCas12a functions
with a sgRNA when delivered as mRNA. Cas12a activ-
ity was shown to be dependent on the stability of the
bound pre-crRNA or crRNA, and although pre-crRNA
was ineffective for Cas12a nuclease activity under stan-
dard conditions, longer heat shocks rescued activity,
indicating a likely kinetics issue with the use of pre-
crRNA. In our experiments, pre-crRNA injection with
ErCas12a mRNA permitted nuclease activity, high-
lighting a difference between other Cas12a related pro-
teins and ErCas12a, either in their ability to bind the
RNA guide stably and access DNA or in the stability
of their respective pre-crRNA structures. Because the
use of multiple crRNAs per target gene in tandem dra-
matically increases the possibility of off-target effects,
it is notable that in this study, ErCas12a displays effi-
cient nuclease activity with only a single pre-crRNA
per target gene.
While ErCas12a showed enhanced activation of SAMR
in comparison with Cas9 in our noto:RFP-DR48 assay, tar-
geted integration via GeneWeld using ErCas12a in zebra-
fish displayed no substantive difference compared to our
previous report using Cas9.19 The increased SAMR fre-
quency detected using the reporter assay may be because
repair of DNA in cis is more efficient than in trans, and
thus the outcome of strand annealing in a genomic reporter
will not translate to targeted integrations.
Reported levels of mosaicism in gene targeting using
HMEJ in zebrafish vary greatly in the literature.15,19
Although ErCas12a is an effective catalyst for GeneWeld
integrations, mosaicism of expression is qualitatively
higher than when using Cas9 as the GeneWeld nucle-
ase.19 Consistent with the observation that SAMR in
noto:RFP-DR48 is mosaic, it was reported recently that
translation of Cas9 mRNA and subsequent gene editing
FIG. 5. Using pMini-CAAGs::RFP-DR48 to assay the propensity of ErCas12a and SpCas9 to elicit strand annealing in
HEK293T cells. (A) Schematic showing the workflow for determining SAMR in human cells. An all-in-one expression
plasmid for ErCas12a or SpCas9 is transfected along with pMini-CAAGs::RFP-DR48. Cells are allowed to recover and
are then isolated with fluorescence-activated cell sorting for RFP+ cells. (B) Quantification of RFP+ cells per total
cells analyzed by flow cytometry. Data plot represents the mean – SD. p-Values calculated with one-tailed Student’s
t-test.
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FIG. 6. Using ErCas12a for targeted integration in human cells. (A) Schematic showing the workflow for targeted
integration at AAVS1 in HEK293T cells. (B) Schematic of AAVS1 showing designed homology for precise integration
using ErCas12a and the U-pre-crRNA to liberate the cassette. Green block, 5¢ homology; blue block, 3¢ homology.
The PAM for ErCas12a targeting in the genome and donor is underlined. (C) Schematic for flow analysis after
transfection of GeneWeld reagents for targeting AAVS1. (D) Bar graph showing the ratio of cells with GFP
expression as determined by flow cytometry. Graph represents the mean – SD. p-Values calculated with one-tailed
Student’s t-test. (E) Junction fragment gel showing the expected 5¢ integration amplicon. No amplicon is seen when
transfecting donor alone. (F) DNA sequencing of lanes in (E) showing a precise integration using the programmed
homology.
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after one-cell stage injection is not complete until the
16- or 32-cell stage, while RNP injections result in appre-
ciable nuclease activity by the two- to four-cell stage.38
Thus, noto:RFP-DR48 is an assay system where injection
conditions can be optimized to enhance somatic gene tar-
geting and decrease mosaicism in cell types that arise
from the mesoderm. Also, noto:RFP-DR48 represents a
novel reporter in zebrafish for determining strategies
for altering DSB repair pathway choice, such as using
small molecules or dominant-negative proteins.
Previously reported Cas12a orthologs have displayed
relatively poor editing efficiency in mammalian sys-
tems.26,27,39,40 AsCas12a and LbCas12a are among the
best characterized Cas12a systems but have very modest
activity in human cells.26,40 To address this issue, addi-
tional Cas12a systems with enhanced activity and differen-
tial targeting ability such as FnCas12a were engineered
and characterized. Although FnCas12a uses a more com-
mon TTN PAM sequence, its cleavage activity is still
modest.39 Editing efficiency of the Cas12a systems has
since been enhanced by engineering the crRNA to increase
activity without a loss of specificity.41 Additionally, recent
work has identified particular point mutations in Cas12a
variants that enhance the targeting range, activity, and
fidelity of the nuclease.42 This suggests the possibility of
a future ErCas12a variant in which cleavage kinetics
could be leveraged with broadened PAM targeting to tar-
get regions typically restricted to SpCas9. Going forward,
it will be interesting to evaluate the effects of various mod-
ifications of crRNAs and the protein itself to optimize mu-
tagenesis and gene targeting.
The five-base thymidine stretch in the secondary
structure of the ErCas12a crRNA could cause cryptic ter-
mination of guide expression43 and lead to decreased
expression of the guide RNA, potentially decreasing nu-
clease activity. Testing crRNA designs that remove this
thymidine stretch may increase crRNA expression and
nuclease efficiency. It has been shown previously that
a single U6 promoter is sufficient to express multiple
crRNAs with Cas12a for multiplex gene editing due to
the intrinsic self-processing activity of the nuclease.2
It is of interest for future investigations to determine if
ErCas12a has similar properties in order to leverage it
for multiplex gene editing.
Interestingly, the RuvC domain in Cas12a family
members is sufficient to elicit indiscriminate ssDNA
and ssRNA cleavage.44 Though ErCas12a shares only
31% sequence homology with Cas12a orthologue
AsCas12a (Supplementary Fig. S1) and the RuvC domain
is conserved among Cas12a orthologues and ErCas12a, it
is possible that long-range interactions at the catalytic
pocket differ in ErCas12a due to the relatively low
amino acid similarity. Therefore, further studies are
needed to elucidate if ErCas12a shares similar nonspe-
cific nuclease activity.
It is notable that in this study, several of the guide
RNAs selected had no activity. When designing guide
RNAs for CRISPR systems, the researcher must consider
two primary factors: on-target (efficiency) and off-target
(specificity) activity of the guide. In this study, we visu-
ally interrogated the target loci for the 5¢-YTTN PAM se-
quence due to the lack of precedent for ErCas12a guide
RNA design. Previous studies with SpCas9 have shown
that nuclease activity has variable activity across differ-
ent target sites, with certain genomic target sites having
inherently more activity,2,3,45–50 and it is likely that sim-
ilar limitations exist with ErCas12a. This and other work
has established approximate guidelines for designing
SpCas9 guide RNAs, including avoiding poly-T se-
quences, limiting GC content, and avoiding a G immedi-
ately upstream of the NGG PAM.51–53 Based on these
studies, several guide RNA design tools such as Guide-
Scan54 and sgRNA Scorer55 were developed to assist in
designing efficient and specific guide RNAs. With further
experimentation, it is likely that design platforms will
likewise be established for ErCas12a guide RNAs.
Tools such as DeepCRISPR56 are utilizing deep learning
algorithms to determine ideal guide RNAs for Cas9 and
could prove to be powerful assets in determining optimal
ErCas12a crRNA design.
Though Cas12a systems have been shown to be
amenable to HDR-mediated integration, these trans-
gene integration events have been shown to be highly
dependent on using RNP complexes in concert with
modified crRNAs to show appreciable activity.27
Here, we demonstrate ErCas12a’s utility in generating
robust editing efficiency without chemically modified
crRNAs, showing its utility in streamlined and accessi-
ble gene editing for most research applications. Further,
we show ErCas12a mediates precise integration with-
out engineering of the nuclease or the corresponding
guide RNA with mRNA and plasmid DNA.
While we show that ErCas12a is compatible with
GeneWeld, we also demonstrate that in the absence
of the UgRNA liberating the donor, there is still inte-
gration of the transgene at AAVS1. When GeneWeld
is used with Cas9, the donor homology arms can include
a portion of the genomic target but exclude the 3¢ PAM
sequence and prevent nuclease targeting at the homol-
ogy arms. However, because ErCas12a utilizes a 5¢
PAM and induces a distal DSB, it is likely that the ho-
mology arm is being targeted by ErCas12a and lineariz-
ing the donor at the 5¢ end. In our design, the homology
arms contain up to 17 bp of the target region that may be
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sufficient for a Cas12a-like seed region for the crRNA
and facilitate a DSB.44,57 These data and previous stud-
ies of other Cas12a proteins suggest that ErCas12a may
elicit measurable off-target activity. As such, future
studies of ErCas12a should include in-depth analysis
for off-target activities, as has been conducted for
other CRISPR systems.46,58 In addition to further opti-
mization of both the crRNA and donor constructs,
ErCas12a can be readily be adapted for precise integra-
tion in mammalian systems.
Conclusion
Alternative nuclease systems beyond canonical CRISPR-
Cas9 are of interest in the precision therapeutics field as
they expand the available toolbox for precision gene edit-
ing. Here, we demonstrate effective genome editing in
both zebrafish and human cells using the newly described
CRISPR-ErCas12a system, which increases the number
of accessible regions in the genome due to its AT-rich
PAM sequence. In zebrafish, CRISPR-ErCas12a pro-
motes efficient somatic mutation and HMEJ-mediated
precise integration of donor cassettes. In human cells,
CRISPR-ErCas12a efficiently targeted therapeutically
relevant loci, including the safe harbor loci AAVS1 and
CCR5, and facilitated transgene integration. Our data
suggest that, with further optimization, ErCas12a may
be an invaluable tool for gene editing in both basic re-
search and future clinical gene therapy applications.
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